Kaylen Meeks

Ms. Kaylen Meeks


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2024 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
KMKaylen Meeks
Kaylen Meeks
JJJuan Ji
Juan Ji
MPMykola V. Protopopov
Mykola V. Protopopov
OTOlga O. Tarkhanova
Olga O. Tarkhanova
YMYurii S. Moroz
Yurii S. Moroz
JTJohn J. Tanner
John J. Tanner


19 November 2022 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
KMKaylen Meeks
Kaylen Meeks
JTJohn J. Tanner
John J. Tanner

25 January 2025 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
KMKaylen Meeks
Kaylen Meeks
JJJuan Ji
Juan Ji
GSGary K. Scott
Gary K. Scott
ACAshley Campbell
Ashley Campbell
JNJay Nix
Jay Nix
JTJohn J. Tanner
John J. Tanner

16 November 2024 in Molecules
Verified
Journal Article
Open access
PDF file
KMKaylen Meeks
Kaylen Meeks
ABAlexandra N. Bogner
Alexandra N. Bogner
JNJay Nix
Jay Nix
JTJohn J. Tanner
John J. Tanner
The proline catabolic pathway consisting of proline dehydrogenase (PRODH) and L-glutamate-γ-semialdehyde (GSAL) dehydrogenase (GSALDH) catalyzes the four-electron oxidation of L-proline to L-glutamate. Chemical probes to these enzymes are of interest for their role in cancer and inherited metabolic disease. Here, we report the results of a crystallographic fragment-screening campaign targeting both enzymes. A unique aspect of our approach is the screening of both enzymes simultaneously using crystals of the bifunctional PRODH-GSALDH enzyme, proline utilization A (PutA). A 288-fragment library from Zenobia was screened in crystallo in cocktails of six fragments. Validation X-ray crystallography with individual fragments identified seven crystal hits distributed in the PRODH active site, GSALDH aldehyde substrate-binding site, and GSALDH NAD+ adenine-binding site. The fragment bound in the PRODH active site, 4-methoxybenzyl alcohol, is structurally distinct from all known PRODH inhibitors as it lacks an anionic anchor and stabilizes open conformations of the active site, motivating the study of eighteen analogs. In total, thirteen crystal structures with resolutions ranging from 1.32 Å to 1.80 Å were determined, resolving the poses and interactions of seven fragments from the Zenobia library and five analogs of 4-methoxybenzyl alcohol. These results expand the chemical space of probes targeting proline catabolic enzymes and provide new structural information for further inhibitor development.

18 March 2026 in Biochemical Journal
Verified
Journal Article
Open access
KMKaylen Meeks
Kaylen Meeks
CMCaitlin J. Mattingly
Caitlin J. Mattingly
JNJay Nix
Jay Nix
OCOleksii Chuk
Oleksii Chuk
MPMykola V. Protopopov
Mykola V. Protopopov
JTJohn J. Tanner
John J. Tanner
Δ1-pyrroline-5-carboxylate (P5C) reductase 1 (PYCR1) catalyzes the NAD(P)H-dependent conversion of L-P5C to L-proline and is one of the most consistently up-regulated metabolic enzymes in cancer cells. High PYCR1 expression is associated with adverse clinical outcomes, and its knockdown inhibits tumor proliferation and metastasis, motivating inhibitor discovery. All structurally validated PYCR1 inhibitors to date bind in the active site and are anchored in the L-P5C binding pocket by an anionic functional group, typically carboxylate. Seeking inhibitors with alternative anchors, we used X-ray crystallography to screen 22 fragment-like compounds (MW = 189–343 Da) from docking that represent six different carboxylic acid isosteres. Surprisingly, only one compound bound in the active site. Four other compounds were found in three adjacent remote sites located in oligomer interfaces. The compounds bind 7 Å from NADH and 10–14 Å from L-P5C, and the intervening space is blocked by protein for inhibitors in Sites 1A/1B and open for inhibitors in Site 2. Together, the three binding sites define a ligand binding hot spot groove that spans 33 Å. The remote binders inhibit PYCR1 activity with K values from the mixed model of inhibition of 32 μM to 2 mM. Co-crystal structures of PYCR1 with combinations of allosteric inhibitors, NADH, and L-P5C/proline analogs suggest the inhibitors can bind to the ternary PYCR1–L-P5C–NAD(P)H complex in addition to the free enzyme, consistent with a mixed mechanism of inhibition. The discovery of an allosteric inhibitor binding groove that accommodates multiple fragments heralds a new era of PYCR1 inhibitor design.